VHH-Based NKp30 Binders for Enhanced NK Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NK cell engagers for cancer treatment face limitations due to insufficient affinity, stability, manufacturability, and specificity, as well as interference from natural ligands, which restrict their effectiveness and practical application.
Innovation Solution
Development of VHH antibody domains or fragments with specific CDR sequences that exhibit high affinity and specificity for NKp30, enhancing NK cell activation and cytotoxicity, while being resistant to natural ligands and improving manufacturability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used for NK cell engagement, then they can bind to CD16a and activate NK cells, but their affinity is insufficient and they are affected by natural ligands and polymorphisms
Solution Approach 1:
The patent changes the molecular parameters by using VHH domains instead of conventional antibodies, achieving higher affinity for NKp30 and resistance to natural ligand interference and polymorphism effects
Solution Approach 2:
The patent extracts the essential antigen-binding function from conventional antibodies by using only the VHH domain, eliminating the problematic Fc region that interacts with CD16a and is susceptible to polymorphisms and natural ligands
2Reliability
If adoptive cell therapy with ex vivo activated NK cells is used, then cancer treatment potential is achieved, but logistic complexity increases
Solution Approach 1:
The patent extracts the NK cell activation function from complex ex vivo protocols by using a simple antibody-based approach that can be administered directly, eliminating the need for complex cell collection, activation, and reinfusion procedures
Solution Approach 2:
The patent introduces an antibody intermediary that bridges the gap between tumor cells and NK cells, enabling activation without direct cell manipulation and simplifying the therapeutic approach
3Reliability
If blocking inhibitory receptors on NK cells is used, then immune cell activation is enabled, but the approach is limited to specific receptor-ligand interactions
Solution Approach 1:
The patent creates a universal approach by targeting CD16a, which is expressed on the vast majority of NK cells, rather than relying on specific inhibitory receptor-ligand interactions, thereby broadening applicability
4Reliability
If conventional antibodies with low affinity for CD16a are used, then ADCC can be induced, but the degree of opsonization is limited
Solution Approach 1:
The patent changes the affinity parameter by using VHH domains with high affinity for NKp30, achieving enhanced opsonization and ADCC induction compared to conventional low-affinity antibodies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The VHH-based compounds demonstrate enhanced NK cell activation, increased cytotoxicity, and improved manufacturability, effectively targeting tumor cells with reduced side effects and increased therapeutic window.
Implementation Method 1
VHH-based NKp30 binders... exhibit high affinity and specificity for NKp30, enhancing NK cell activation and cytotoxicity
Data Source
AI summary
VHH-based NKp30 binders are provided having favorable characteristics. Moreover, pharmaceutical compositions including such a compound are produced and methods of medical treatment with such compounds and pharmaceutical compositions are developed. In a compound including a VHH antibody domain or fragment thereof, the VHH antibody domain or fragment thereof can have complementary determining regions CDR1, CDR2, and CDR3 of one of VHH1 to VHH16, or a humanized modification thereof, or a modification involving replacement, addition, and/or deletion of up to three amino acids in each complementary determining region.